Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Naoki Kotani"'
Autor:
Naoki Kotani, Kiyomi Ito
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 8, Pp 1359-1368 (2023)
Abstract In vitro potency is one of the important parameters representing efficacy potential of drugs and commonly used as benchmark of efficacious exposure at early clinical development. There are limited numbers of studies which systematically inve
Externí odkaz:
https://doaj.org/article/9ee9a74f83bd45ce8c30189a3b9e232f
Autor:
Robin J Svensson, Jakob Ribbing, Naoki Kotani, Michael Dolton, Shweta Vadhavkar, Dorothy Cheung, Tracy Staton, David F Choy, Wendy Putnam, Jin Jin, Nageshwar Budha, Mats O. Karlsson, Angelica Quartino, Rui Zhu
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1221-1235 (2021)
Abstract Identification of covariates, including biomarkers, spirometry, and diaries/questionnaires, that predict asthma exacerbations would allow better clinical predictions, shorter phase II trials and inform decisions on phase III design, and/or i
Externí odkaz:
https://doaj.org/article/99d33c6d1f7e4cdfb4ba2b342953726c
Autor:
Naoki Kotani, Justin J. Wilkins, Janet R. Wade, Steve Dang, Dhruvitkumar S. Sutaria, Kenta Yoshida, Sameer Sundrani, Hao Ding, Josep Garcia, Heather Hinton, Rucha Sane, Pascal Chanu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 90:511-521
Purpose The exposure–response relationships for efficacy and safety of ipatasertib, a selective AKT kinase inhibitor, were characterized using data collected from 1101 patients with metastatic castration-resistant prostate cancer in the IPATential1
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 384:187-196
Autor:
Il-Sung Jang, Norio Akaike, Hisahiko Kubota, Hironari Akaike, Naoki Kotani, Kiku Nonaka, Nobuharu Okamitsu
Publikováno v:
Brain Research Bulletin. 157:51-60
Effects of xenon (Xe) on whole-cell currents induced by glutamate (Glu), its three ionotropic subtypes, and GABA, as well as on the fast synaptic glutamatergic and GABAergic transmissions, were studied in the mechanically dissociated "synapse bouton
Autor:
Cristina Saura, Mafalda Oliveira, Valentina Gambardella, Kevin Kalinsky, Andrés Cervantes, Naoki Kotani, Ian E. Krop, Zachary William Neil Veitch, Komal Jhaveri, Dejan Juric, Erika Hamilton, Antoine Italiano, Anjali Vaze, Stephanie Royer-Joo, Katie Hutchinson, Peter Schmid, Philippe L. Bedard, Jennifer L. Schutzman, Nicholas C. Turner, Andrea Varga, Amy V. Kapp, Leslie J. Dickmann
Publikováno v:
Cancer Research. 80:P1-19
Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models
Autor:
Erika Hamilton, Mafalda Oliveira, Andrés Cervantes, Amy V. Kapp, Jennifer L. Schutzman, Nicholas C. Turner, Naoki Kotani, Zachary William Neil Veitch, Ian E. Krop, Dejan Juric, Antoine Italiano, Stephanie Royer-Joo, Komal Jhaveri, Philippe L. Bedard, Anjali Vaze, Peter Schmid, Katie Hutchinson, Kevin Kalinsky, Leslie J. Dickmann, Jill Fredrickson, Andrea Varga, Valentina Gambardella, Cristina Saura
Publikováno v:
Cancer Research. 80:OT1-08
Background: Activating mutations in PIK3CA, encoding the p110α subunit of phosphatidylinositol 3-kinase (PI3K), are highly prevalent in breast cancer and solid tumor malignancies. GDC-0077 is a potent p110α-selective inhibitor with a novel mechanis
Autor:
Naoki Kotani, Michael Dolton, Robin J. Svensson, Jakob Ribbing, Lena E. Friberg, Shweta Vadhavkar, Dorothy Cheung, Tracy Staton, Gizette Sperinde, Jin Jin, Wendy S. Putnam, Angelica Quartino
Publikováno v:
Journal of clinical pharmacology. 62(7)
Astegolimab is a fully human immunoglobulin G2 monoclonal antibody that binds to the ST2 receptor and blocks the interleukin-33 signaling. It was evaluated in patients with uncontrolled severe asthma in the phase 2b study (Zenyatta) at doses of 70, 2
Autor:
Weize Huang, Junyi Li, Michael Z. Liao, Stephanie N. Liu, Jiajie Yu, Jing Jing, Naoki Kotani, Lynn Kamen, Sebastian Guelman, Dale R. Miles
Publikováno v:
Clinical pharmacology and therapeutics. 112(5)
Adoptive cell therapies (ACTs) have shown transformative efficacy in oncology with five US Food and Drug Administration (FDA) approvals for chimeric antigen receptor (CAR) T-cell therapies in hematological malignancies, and promising activity for T c
Autor:
Naoki Kotani
Publikováno v:
Transactions of the Institute of Systems, Control and Information Engineers. 33:317-319